SCHEMBL10132876

SCHEMBL10132876

F/C(=C\Cc1ccccc1)Cc1ccc(-c2ccc(OCN3CCOCC3)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.54
ESR2 Q92731 2/20 0.54
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
PKM P14618 1/20 0.46
LTA4H P09960 1/20 0.46
EGFR P00533 2/20 0.43
EPHX2 P34913 1/20 0.42
MAPT P10636 2/20 0.42
FAAH O00519 1/20 0.42
MGLL Q99685 1/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
ABL1 P00519 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
LYN P07948 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
BCR P11274 1/20 0.41
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132871 0.89 NPC1 (0.62) ESR1NPC1RAB9ALTA4HEPHX2
SCHEMBL10132935 0.89 EPHX2 (0.57) NPC1RAB9ALTA4HEPHX2ALDH1A1
SCHEMBL10132875 0.79 SRC (0.58) NPC1RAB9ALTA4HEPHX2ABL1
SCHEMBL10132873 0.78 TUBB4A (0.66) NPC1RAB9ALTA4HEPHX2ABL1
SCHEMBL10132938 0.77 NPC1 (0.47) NPC1RAB9ALTA4HABL1TUBB4A
SCHEMBL10133002 0.77 LTA4H (0.60) NPC1RAB9ALTA4H
SCHEMBL10132881 0.77 ESR1 (0.55) ESR1ESR2NPC1RAB9APKM
SCHEMBL10132914 0.76 SRC (0.64) ESR1ESR2NPC1RAB9AEPHX2
SCHEMBL10132913 0.76 SRC (0.64) ESR1ESR2NPC1RAB9AEPHX2
SCHEMBL10132882 0.75 ESR1 (0.53) ESR1ESR2NPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-8124605-B2 Compositions and methods for modulating a kinase cascade KINEX PHARMACEUTICALS, LLC (US) 2012-02-28 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed
US-20090149510-A1 Compositions and methods for modulating a kinase cascade OAKTREE FUND ADMINISTRATION, LLC 2009-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149510-A1 Compositions and methods for modulating a kinase cascade MAP3K6, MAP3K4, MAP3K3 ESR1 1277/4885ESR2 1738/4885NPC1 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.